These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5253 related articles for article (PubMed ID: 3544990)

  • 1. Noninvasive evaluation of peripheral vasculature following regional hyperthermic chemotherapeutic perfusion (RHCP).
    Muchmore JH; Krementz ET; Kerstein MD
    Am Surg; 1987 Feb; 53(2):94-6. PubMed ID: 3544990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
    Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
    Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities.
    Papa MZ; Klein E; Karni T; Koller M; Davidson B; Azizi E; Ben-Ari G
    Am J Surg; 1996 Apr; 171(4):416-20. PubMed ID: 8604833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
    Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
    Haier J; Hohenberger P; Beck K; Schlag PM
    Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response.
    Aloia TA; Grubbs E; Onaitis M; Mosca PJ; Cheng TY; Seigler H; Tyler DS
    Arch Surg; 2005 Nov; 140(11):1115-20. PubMed ID: 16301451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
    Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
    Vrouenraets BC; in't Veld GJ; Nieweg OE; van Slooten GW; van Dongen JA; Kroon BB
    Eur J Surg Oncol; 1999 Oct; 25(5):503-8. PubMed ID: 10529261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP).
    Knorr C; Melling N; Goehl J; Drachsler T; Hohenberger W; Meyer T
    Int J Hyperthermia; 2008 Aug; 24(5):409-14. PubMed ID: 18608587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic perfusion of recurrent malignant melanoma on the extremities.
    Hafström L; Jönsson PE
    Acta Chir Scand; 1980; 146(5):313-8. PubMed ID: 7468061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs.
    Vrouenraets BC; Eggermont AM; Klaase JM; Van Geel BN; Van Dongen JA; Kroon BB
    Eur J Surg Oncol; 1994 Dec; 20(6):681-5. PubMed ID: 7995421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 263.